Capricor Therapeutics (NASDAQ:CAPR) Shares Down 4.7% - Here's Why

Capricor Therapeutics Inc (NASDAQ:CAPR - Get Free Report) shares traded down 4.7% during mid-day trading on Friday . The stock traded as low as $12.25 and last traded at $12.15. 363,080 shares traded hands during mid-day trading, a decline of 76% from the average session volume of 1,502,834 shares. The stock had previously closed at $12.74.

Analyst Ratings Changes

CAPR has been the topic of several analyst reports. Cantor Fitzgerald reaffirmed an "overweight" rating and issued a $30.00 target price on shares of Capricor Therapeutics in a report on Thursday, March 20th. HC Wainwright restated a "buy" rating and issued a $77.00 price target on shares of Capricor Therapeutics in a research note on Monday, March 17th. One investment analyst has rated the stock with a sell rating and six have assigned a buy rating to the company. Based on data from MarketBeat.com, the company has an average rating of "Moderate Buy" and a consensus price target of $34.50.

Capricor Therapeutics Price Performance

The stock has a market cap of $338.92 million, a PE ratio of -7.04 and a beta of 0.85. The stock has a 50-day simple moving average of $11.44 and a 200-day simple moving average of $14.42.

Capricor Therapeutics (NASDAQ:CAPR - Get Free Report) last released its quarterly earnings data on Wednesday, March 19th. The biotechnology company reported ($0.16) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.31) by $0.15. The company had revenue of $11.13 million during the quarter, compared to the consensus estimate of $9.87 million. Capricor Therapeutics had a negative net margin of 146.86% and a negative return on equity of 112.95%. As a group, equities research analysts anticipate that Capricor Therapeutics Inc will post -1.21 EPS for the current year.

Hedge Funds Weigh In On Capricor Therapeutics

Institutional investors have recently added to or reduced their stakes in the company. Vanguard Group Inc. grew its position in shares of Capricor Therapeutics by 44.4% during the 4th quarter. Vanguard Group Inc. now owns 2,276,784 shares of the biotechnology company's stock valued at $31,420,000 after buying an additional 700,243 shares during the last quarter. Farallon Capital Management LLC acquired a new stake in shares of Capricor Therapeutics in the 4th quarter worth approximately $31,056,000. Geode Capital Management LLC raised its holdings in Capricor Therapeutics by 37.8% during the fourth quarter. Geode Capital Management LLC now owns 879,468 shares of the biotechnology company's stock worth $12,139,000 after purchasing an additional 241,279 shares in the last quarter. Altium Capital Management LLC increased its position in shares of Capricor Therapeutics by 150.5% during the 4th quarter. Altium Capital Management LLC now owns 714,000 shares of the biotechnology company's stock valued at $9,853,000 after purchasing an additional 429,000 shares during the period. Finally, Woodline Partners LP acquired a new position in Capricor Therapeutics during the fourth quarter worth about $8,693,000. Institutional investors and hedge funds own 21.68% of the company's stock.

About Capricor Therapeutics

Capricor Therapeutics, Inc NASDAQ: CAPR is a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class biological therapeutics for the treatment of rare disorders. Capricor's lead candidate, CAP-1002, is an allogeneic cell therapy that is currently in clinical development for the treatment of Duchenne muscular dystrophy.